NIH-funded, AI-powered analysis of interviews suggests that a youth’s framing of stressful events is a strong indicator of risk for future disorders.

JULY 31, 2026 – By applying artificial intelligence (AI) techniques to interviews with children about early life stress, researchers identified linguistic features that predicted future depressive or anxiety disorders. In a National Institutes of Health (NIH)-funded study, scientists developed predictive models based on these features that could predict symptom onset and diagnosis up to six years later, surpassing estimates based on gold-standard risk indicators.

This new research, led by senior author Ian H. Gotlib, Ph.D., at Stanford University, may represent a better way of identifying children without mental health disorders but are at high risk of developing them later in life. Such a tool could enable healthcare providers to act during a crucial window when prevention is still possible — a capability not supported by current clinical assessments.

“We know that exposure to early adversity is a potent risk factor for the development of mental health problems. At the same time, many children experience adversity but do not go on to develop psychopathology. With current methods, which rely heavily on static risk factors, we cannot reliably distinguish children who are at risk from those who are likely to be resilient,” said first author Chase Antonacci, a Ph.D. candidate at Stanford University.

Seeking objective, data-driven factors that are more indicative of an individual’s risk, the authors searched for answers in language, wherein subtle cues have potentially been overlooked.

The researchers analyzed audio recordings of structured interviews with 204 children, 9 to 13 years old, enrolled in the NIH-supported Early Life Stress Study. The interviews, about 30 minutes on average, covered each child’s lifetime exposure to traumatic events, providing a measure of baseline stress when children were not yet diagnosed with any mental health disorder. The team also obtained data from follow-up assessments conducted either four or six years later.

Antonacci and his colleagues applied four different natural-language processing techniques to search for patterns within the audio recordings. These AI tools were sensitive to an array of properties, such as sentence structure, grammar, semantics, topics, and categories of words.

By attempting to predict mental health outcomes at the four- and six-year follow-up assessments with each model, the authors identified which features of language were the strongest indicators of risk. For comparison, they also attempted to accomplish the same goal with only demographic information and stress severity scores that experts produced based on the interviews.

The team found that linguistic style was paramount.

One of the strongest predictors was elevated narrative complexity, marked by greater use of function words such as prepositions, which may indicate styles of thinking, including rumination, that are well-established risk factors of depression. Other robust markers included the use of rigid language that expressed absolute certainty and self-referential speech indicated by heavy use of first-person singular pronouns.

“We saw that the way kids spoke about stress exposure — the mechanics of their language, rather than necessarily what they said — was a robust predictor of the onset of anxiety and depression,” Antonacci said.

Semantic models linked specific themes to mental health outcomes. While narratives about routine engagement with hobbies, structured activities, and access to healthcare seemingly had a protective effect, those about acute physical violence and social exclusion steered children in the opposite direction.

In many cases, the researchers showed that their predictive models outperformed predictions based on expert ratings, the gold-standard measurement of stress severity. In the future, the researchers aim to boost performance further by integrating their models.

“A method of predicting which children are most vulnerable to developing mood and anxiety disorders would be tremendous in helping to prevent a possible burden of cost and suffering over a lifetime,” said Andrea Beckel-Mitchener, Ph.D., acting director of NIH’s National Institute of Mental Health (NIMH).

NIH supported this research through NIMH grants R37MH101495 and F32MH135657.

About the National Institute of Mental Health (NIMH): The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure. For more information, visit the NIMH website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

Reference

Chase Antonacci et al. Natural Language Processing of Youth Speech Predicts Psychopathology Across Adolescence. Nature Mental Health. July 31, 2026. DOI: 10.1038/s44220-026-00683-9




Insurance approval delays and a lack of options for care after leaving the hospital are the most significant factors delaying patient recovery

JULY 29. 2026 – Tallahassee, Fla. —  Florida’s congressional delegation urged the Centers for Medicare and Medicaid Services (CMS) to approve and renew critical funding for graduate medical education (GME) programs in Florida.

U.S. Rep. Aaron Bean spearheaded the request and worked closely with the Florida Hospital Association (FHA) to gather signatures from the delegation on a letter to CMS that urged the agency to work closely with the Florida Agency for Health Care Administration (AHCA) to advance critical Medicaid funding for several GME programs that train the next generation of physicians. Medicaid currently helps fund the training of more than 7,000 medical residents statewide. More than 60% of medical residents end up staying and practicing where they did their medical residency. Building and sustaining graduate medical education training for the next generation of physicians is key to addressing the ever-growing demand for healthcare in Florida.

Florida has been disadvantaged for decades by a 30-year-old Medicare funding formula that historically favors states like Massachusetts and New York with established graduate medical education programs. Florida’s population has grown by nine million people in the last 30 years without the benefit of critical federal Medicare funding to help train physicians and support our physician workforce needs.

The Florida Legislature wisely understood they could not wait for the federal government to address this out-of-date formula and established state-sponsored and Medicaid-funded graduate medical education programs. CMS is now withholding support for new GME programs and requiring long-established programs to sunset pending federal approval of some yet-to-be-determined new methodology.

Florida faces a physician shortage that is larger than either Texas or California.  “For patients, these shortages translate into longer wait times for appointments, delayed diagnoses, overcrowded emergency departments, and more difficulty accessing specialty care,” said Mary Mayhew, President and CEO of FHA. “As one of the fastest growing states in the country, Florida’s demand for physicians continues to grow as well. A physician shortage is projected to reach 32,000 by 2038.”

In their letter to CMS Administrator Dr. Mehmet Oz, members of Florida’s congressional delegation highlighted the importance of the GME program explaining that, “this financing system rewards historical training capacity rather than current healthcare needs, preserving structural inequities that make it substantially more difficult for high-growth states to train the physicians their residents need today.”
“Every day the federal government continues to delay their approval of this funding is another day we lose to not training the primary and specialty care physicians needed to meet the medical needs of Florida’s rapidly growing and aging population,” she added.

At a time when Florida faces one of the nation’s most significant physician shortages, preserving Medicaid-funded graduate medical education is more important than ever. Prompt CMS action will help ensure hospitals can continue training the physicians needed to meet the health care demands of Florida’s growing population and safeguard access to care for patients throughout the state.

ABOUT FHA

Founded in 1927, the Florida Hospital Association (FHA) is the leading voice for health care in the State of Florida. Through representation and advocacy, education and informational services, the Florida Hospital Association supports the mission of over 260 hospitals and health care systems to provide the highest quality of care to the patients we serve. Led by President and CEO Mary Mayhew, the Florida Hospital Association is located in Tallahassee and is governed by a Board of Trustees and officers elected by the member institutions. To learn more, visit www.fha.org.




BY: Alison Satake

JULY 29, 2026 – ROCHESTER, Minn. — A series of Mayo Clinic studies is helping reshape scientists’ understanding of senescent, or “zombie,” cells — aging cells that no longer divide but remain metabolically active and release inflammatory molecules that contribute to age-related diseases.

portrait of Dr. Marissa Schafer
Marissa Schafer, Ph.D.

Published across Nature journals, the studies authored by scientists within the Robert and Arlene Kogod Center on Aging move the field beyond recognizing that senescent cells contribute to aging. Together, they provide new tools to identify these cells, uncover mechanisms that drive inflammation and explore strategies to reduce their effects in preclinical models. In collaboration with researchers across the U.S., they are part of an ambitious project to map senescent cells across different tissues. The project is called the Cellular Senescence Network (SenNet) Consortium and is funded by the National Institutes of Health Common Fund. Its primary objective is to compile comprehensive atlases of senescent cells within the human body over a lifetime.

“This body of work is moving the aging field forward to precisely identify, understand and target the specific senescent cells that contribute to age-related dysfunction, which is the necessary groundwork to develop new therapies that support healthy aging,” says Marissa Schafer, Ph.D., a Mayo Clinic researcher whose laboratory led several of the studies.

Exploring new therapeutic strategies

Several studies evaluated approaches designed to reduce the burden or harmful effects of senescent cells in preclinical models.

The research examined interventions, including senolytic drugs, a naturally occurring compound found in tomatoes, and genetic approaches that selectively target senescent cells. In aged mice, these strategies reduced measures of inflammation and improved outcomes associated with aging, including physical frailty, brain inflammation and cognitive performance.

Another study identified IL-23R as a potential blood biomarker that could one day help researchers assess biological aging and monitor responses to future therapies.

Although additional research is needed before these findings can be translated to patient care, the studies provide a stronger scientific foundation for developing more targeted interventions for age-related diseases.

Dr. Schafer is the senior author of the following papers:

Revealing why senescent cells drive inflammation

Additional studies uncovered previously unknown mechanisms that help explain why senescent cells produce persistent inflammation.

Researchers found that dysfunctional mitochondria — the structures that generate energy inside cells — contribute to inflammation through multiple pathways. One mechanism involves mitochondrial DNA and RNA activating immune signaling. Another shows that mitochondrial metabolism changes how inflammatory genes are activated through epigenetic regulation.

Together, these discoveries identify potential therapeutic targets that could reduce harmful inflammation without necessarily eliminating senescent cells.

João Passos, Ph.D., is the senior author of the following papers:

A growing body of research

Taken together, these studies advance the field from demonstrating that senescent cells contribute to aging toward understanding which senescent cells matter most, how they drive disease and how they may be targeted more precisely.

Portrait of Dr. Darren Baker
Darren Baker, Ph.D.

Rather than focusing solely on eliminating senescent cells, the research supports a more nuanced approach that aims to identify the biological pathways responsible for harmful inflammation and develop therapies that selectively interrupt those processes.

Darren Baker, Ph.D., a Mayo Clinic researcher, is the senior author of the paper, “Senotypes define the diverse landscape of senescent cells.”

The research is part of a larger effort at Mayo Clinic called the Precure Research initiative, which is focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.

Review the studies for a complete list of authors, disclosures and funding.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.




BY: Caroline Auger

JULY 30, 2026 – SAO PAULO and ROCHESTER, Minn. — Mayo Clinic and Einstein Hospital Israelita today announced a milestone in their collaboration to advance responsible artificial intelligence (AI)-enabled healthcare innovation. Einstein’s de-identified clinical data is now available through Mayo Clinic Platform‘s secure, privacy-preserving global healthcare innovation ecosystem. The collaboration strengthens South American representation in global health datasets and enables researchers and innovators to develop, validate, and scale AI-enabled solutions across a broader representation of patient populations.

“Working with leading hospitals around the world, like Einstein Hospital Israelita, Mayo Clinic Platform is curating the world’s data and assembling the world’s innovators to advance healthcare transformation,” says John Halamka, M.D., Dwight and Dian Diercks president, Mayo Clinic Platform. “By building a global health data network, we can accelerate the discovery, development and deployment of trusted AI-enabled solutions to improve care for patients everywhere.”

For Einstein Hospital Israelita, the milestone reinforces its role as one of the global and leading institutions in health innovation, enabling the development and validation of AI-enabled solutions through Mayo Clinic Platform’s secure environment while contributing regional clinical perspectives to global research. The collaboration also creates opportunities for multicenter studies, responsible algorithm validation and future innovation opportunities to connect healthcare professionals, researchers and digital health innovators.

To prepare for this data collaboration, Einstein Hospital Israelita joined Mayo Clinic Platform’s Early Adopter Program to learn how to best use the Platform’s tools and capabilities to advance global AI research.

“Einstein is now taking a more strategic role in one of the most relevant global health data networks focused on innovation. This advancement marks the completion of a technological adaptation stage for secure cloud data access and paves the way for the development, validation, and implementation of AI-based solutions and algorithms. It will also enable secure multicenter studies with privacy protection to advance medical practice, resulting in greater capacity to scale projects to global standards,” says Sidney Klajner, president of Einstein Hospital Israelita.

This global health data network, called Mayo Clinic Platform_Connect, now includes eight members and spans seven countries across three continents. Connect brings broad representation in genetics, demographics and lifestyles to provide a massive repository of analyzable data for research and responsible AI development to transform healthcare globally. All data remains de-identified and under the control of each participating healthcare organization.

Connect’s founding members include Brazil’s Einstein Hospital Israelita, Canada’s University Health Network, Israel’s Sheba Medical Center, Mayo Clinic and Mercy in the United States. Additional partners include Aga Khan University in Kenya and Seoul National University Hospital in South Korea.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Platform
Mayo Clinic Platform is a strategic initiative of Mayo Clinic that enables collaboration, data-driven innovation and responsible AI development to transform healthcare globally. Mayo Clinic Platform is reimagining healthcare as an ecosystem — one where data, digital solutions, and expertise flow seamlessly between innovators and care teams to improve care for patients everywhere.

About Einstein Hospital Israelita
Einstein Hospital Israelita is one of Latin America’s leading healthcare, education, research and innovation institutions. Based in Sao Paulo, Brazil, Einstein combines high-complexity care, scientific research, digital health capabilities and partnerships with global organizations to advance healthcare transformation. Through initiatives in artificial intelligence, data science, technology validation and innovation, Einstein works to translate knowledge into better care, broader access and improved outcomes for patients in Brazil and beyond.




JULY 30, 2026 – Siemens Healthineers and Cleveland Clinic are expanding their 35-year relationship through a new 10-year, strategic alliance designed to foster clinical and workflow innovation that further enhances patient care and operational efficiency across the health system’s locations. Through this strategic alliance, the organizations will work together to build on Cleveland Clinic’s leadership in diagnostic imaging, cardiology and radiation oncology, provide clinical teams with innovative tools and advanced training, and create a more personalized experience for patients.

Under the strategic alliance, Siemens Healthineers will provide multiple diagnostic imaging and therapeutic technologies to Cleveland Clinic, including magnetic resonance imaging, computed tomography, radiation oncology, interventional radiology, and X-ray. In addition, Siemens Healthineers will expand its existing team of more than 30 employees dedicated to supporting Cleveland Clinic. The on-site presence will include technicians and training personnel, including expertise to support Cleveland Clinic’s development of a theranostics cancer-treatment program, an emerging approach that combines targeted imaging and therapy to personalize cancer care.

“This strategic alliance with Siemens Healthineers will help us bring more consistent, connected and advanced imaging and treatment services to our patients,” said Peter Liu, M.D., Chair of Enterprise Imaging at Cleveland Clinic. “By aligning technology, service and clinical support more closely across our global health system, we can improve access, increase efficiency and create a better experience for patients. This collaboration builds on a strong foundation and positions us to continue innovating for the benefit of our patients and communities.”

Added John Kowal, president and head of the Americas at Siemens Healthineers: “Through our longstanding relationship with Cleveland Clinic we have achieved important advances in the diagnosis and treatment of serious disease resulting from more than 100 research projects and 70 peer reviewed publications. We look forward to many more years of innovation and continued positive impact on patient care.”

Additional areas of collaboration include supporting establishment of Cleveland Clinic as a Center of Excellence for MRI technologist education, including providing expertise in ongoing clinical education, protocol optimization, technologist skill development, radiation-safety education, and support for physicians in expanding the use of CT into cardiology, radiation therapy and image-guided procedures.

The strategic alliance is also expected to create opportunities for research, education, workforce development, and a foundation for innovation in the integration of intelligent software and automation into imaging workflows. Siemens Healthineers and Cleveland Clinic are also exploring future initiatives focused on biomedical engineering training and clinical education geared toward workforce development, both at Cleveland Clinic and in the greater Cleveland region. The alliance will also contribute to broader economic development through investment in Cleveland Clinic’s Main Campus, job creation and continued growth in the Cleveland Innovation District.

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.

Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.

About Siemens Healthineers

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.